Jonathan G. Stine, MD MSc, FACP
@JonathanStineMD
Followers
3K
Following
13K
Media
975
Statuses
6K
Global Clinical Program Lead – Late CVRM @AstraZeneca | #MASH researcher | Clinical Professor of Medicine @Penn_State | #exercise #garden #read | Views my own
Gaithersburg, MD
Joined July 2019
So excited to see this out. A fantastic patient-centric, physician-friendly approach to all things nutrition in MASLD. Led by @KatrinaPekarska with incredible co-authors @josewillemse @stumcp @JVLazarus @JonathanStineMD //fg.bmj.com/content/early/2025/11/30/flgastro-2025-103183
0
16
32
PICKLEBALL TOURNAMENT Game on — almost! 🎾 The final day to sign up for the TLM Pickleball Tournament is TOMORROW Oct. 24. Grab your paddle and claim your place on the court! 👉 Register now:
1
1
10
Just over 6 wks until @AASLDtweets #TLM25 in DC! Please join me Nov 9 to hear about "Elements of #MASLD/MASH for Pediatric & Adult Patients" and Nov 10 for "Early Career Investigator Essentials: Adapting & Excelling in Challenging Times." https://t.co/kvXXDHhvg5
1
0
6
SR +MA from @HallsworthKate shows digital behavior change interventions haven’t yet improved weight or liver outcomes in #MASLD, but promising features include app delivery, longer duration, self-monitoring & social support. Innovation still needed here! https://t.co/TRS0ES6ydy
0
5
13
#Exercise FTW! 💪🏃🏋️♀️
🚨 New Publication! 🚨 Our study in @DDS_Journal shows that aerobic exercise training can drive MASH resolution, independent of weight loss, using the validated MASH-Resolution Index (MASH-RI) Grateful to an incredible team for their guidance and vision. @JonathanStineMD
0
5
23
MASLD has become the most common chronic liver disease worldwide. Giovanni Targher, MD, Luca Valenti, MD (@lucavalenti75), and Christopher D. Byrne, MB, ChB, review the features of the disease as well as pharmacotherapies targeting the associated liver and
4
395
1K
Congrats to all who received @AASLDtweets #TLM2025 abstract acceptances yesterday! Looking forward to catching up on all that is new in Hepatolgoy this November in DC!
1
1
24
What if you could reverse liver disease? By 2030, one in two adults is expected to have chronic liver disease. Penn State's @JonathanStineMD is using exercise as medicine to stop damage before it becomes deadly.
psu.edu
Penn State research explores how therapeutic exercise helps improve liver health and manage fatty liver disease.
2
2
10
Global Clinical Program Lead = Global Development Senior Medical Director for those who have reached out to ask!
1
0
8
After 8 yrs in academic medicine, I'm absolutely delighted to announce I’ve joined @AstraZeneca as a Global Clinical Lead. Starting today, I hope to advance innovative therapies for liver & metabolic diseases alongside an incredible team. Onward to this new chapter! #MASLD #MASH
15
5
159
Celebrated 8 incredible years of Stine Lab with a team lunch today! Grateful for the hard work, discoveries, and camaraderie that made our journey so impactful. Here’s to the science, the memories, and the friendships that last far beyond the lab. #MASLD #Research @PennStHershey
3
1
33
Thanks again for your interest in our work! Appreciate the chance to speak with the @GastroHep team about #exercise and #MASLD
“Exercise in Patients With Metabolic Dysfunction-Associated Steatohepatitis” with Jonathan G. Stine, MD, MSc https://t.co/fvdcNdaGZw
@JonathanStineMD @PennStHershey #MASH
0
1
8
New national survey of hepatology & GI providers: Despite 96% believing weight loss meds help #MASLD, 77% rarely/never prescribe them due to low comfort & limited training. Hunge thanks to @geneyim @MeenaBBansal for leading this effort 👉
journals.lww.com
(MASLD), FDA-approved medications for weight loss remain underutilized. Results: We conducted a survey before resmetirom approval of hepatology and gastroenterology providers practicing in 44 states....
1
6
31
Honored to receive the Hepatology Resident of the Year award last night. Deeply grateful to @PennStIMchiefs and @PennStGastroHep for the recognition. Thank you to my family, friends, and mentors, especially my dad and @JonathanStineMD, for your unwavering support and inspiration!
2
2
20
@shivaramsingh @PrajnaAnirvan @JonathanStineMD @EASLnews @AASLDtweets @APASLnews So important to have real-world evidence on lifestyle interventions to further support the guidelines: https://t.co/cyPsrdsbPh
@EASLedu @AlinaAllenMD
@brennap9 #liverTwitter
journals.lww.com
d steatotic liver disease/NAFLD management guidelines published between January 1, 2013, and June 31, 2024, through databases including PubMed/MEDLINE, Cochrane, and CINAHL. In total, 35 qualifying...
0
2
11
👆Happy to share this latest publication from our group. This publication is very dear to me. Grateful to all my coauthors but especially to @PrajnaAnirvan for his tireless efforts in getting this published. @JonathanStineMD This is esp for you @EASLnews @AASLDtweets @APASLnews
9
15
56
MASH day was incredible! I learned so much today from Dr. Stine, Dr. Alkhouri, and Dr. Rotman - truly inspiring! @JonathanStineMD @AlkhouriNaim @NASH_and_coffee @PennStateGME @PennStIMchiefs
Just a couple of #liver docs spending a Thursday together discussing all things #MASLD #MASH here @PennStHershey #MASHDay2025 @NASH_and_coffee @AlkhouriNaim @ChannapragadaV
0
2
11
Session #1 on epidemiology and clinical perspectives in #MASLD is in the books for @PennStHershey #MASHDay. Incredible talks and discussion from the audience and panelists! @KofiClarkeMD @ChannapragadaV @NASH_and_coffee @AlkhouriNaim
1
1
10
Just a couple of #liver docs spending a Thursday together discussing all things #MASLD #MASH here @PennStHershey #MASHDay2025 @NASH_and_coffee @AlkhouriNaim @ChannapragadaV
0
2
31